The commissioner of the US Food and Drug Administration (FDA), Marty Makary, is expected to leave the administration of Donald Trump, after the US president has approved the plan for his dismissal, US media reports, citing sources familiar with the situation.

According to reports, Makary had long been under constant pressure both from within the administration and from outside interest groups. One of the main clashes involved his stance against approving the sale of flavored e-cigarettes, an issue that reportedly brought Trump into direct confrontation with him.

He also faced criticism from the pharmaceutical industry and anti-abortion groups, while his tenure at the FDA was characterized by frequent top management changes and infighting.

Makary’s departure creates another vacancy. in the leadership structures of the US Department of Health and Human Services. Currently, the US administration does not yet have a permanent head of the Centers for Disease Control and Prevention (CDC), as well as the post of surgeon general.

His resignation comes just one day before Makary testifies before the Senate Budget Committee regarding the proposed FDA budget.

According to Politico reports, efforts to remove him have intensified in recent days by a group of House officials. White House and the Health Department, who were unhappy with the agency’s direction and confusion over its policies.

However, some Trump advisers had argued that firing a top health official could have political consequences, particularly angering supporters of the Make America Healthy Again movement associated with Health Secretary Robert F. Kennedy Jr..

One of the issues that accelerated tensions was the refusal of Makary to approve fruit-flavored e-cigarettes. According to sources, Trump personally pressured him on the issue, while the FDA later changed its stance on the products in question.

Another clash was related to the debate over the abortion pill mifepristone. Anti-abortion activists called on the administration to ask the FDA to rescind rules allowing the mail order of the drug, which is widely used for medical abortions in the US.

Susan B. Anthony Pro-Life America president Marjorie Dannenfelser had publicly called for Makary’s firing, accusing him of being unresponsive to the demands of the anti-abortion movement.

Makary, a surgeon and author, had pledged after his appointment in 2025 that he would speed up the approval processes of medicines, medical devices and vaccines. However, during his tenure he faced constant criticism from both pharmaceutical companies, vaccine critics and social conservative groups. /tch

We use cookies to improve the experience and to display advertisements (Google AdSense).
By clicking “Accept”, you agree to the use of cookies according to
Privacy Policy
and
Cookies Policy.
You can reject non-necessary cookies by clicking “Reject”.

Source: prizrenpost